Abstract:
The effect of Nucleinat included in the basic therapy of bronchial asthma (BA) has been analyzed by means of double-blind, placebo-controlled method in 98 school age children. Two clinical groups were formed with the help of the table accidental numbers. The application of the Nucleinat in complex anti-inflammatory therapy of the BA was accompanied by decrease of bronchial hyperresponsiveness due to the possible reduction of the inflammatory process activity in the airways. The use of Nucleinat in the basic therapy of the school-age children significantly reduced the risk of moderate bronchial responsiveness: DAR – 28,5%, DRR – 54,8%, MNT – 1,8 (95% CІ 0,1-7,1).
